Agoracom Blog
«
»

VIDEO – Novamind $NM.ca $NVMDF Discusses Partnership with Merck for New Treatment-Resistant Depression Trial $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 5:22 PM on Monday, March 22nd, 2021

Last week Novamind (NM: CSE:) (NVMDF: OTC) (HN2: FSE) announced that its wholly-owned subsidiary, Cedar Clinical Research has been selected as a key research site for a clinical trial focused on treatment-resistant depression by Merck & Co., a world-leading pharmaceutical company.

The phase II study will assess the efficacy and safety of a new Merck drug for treatment-resistant depression (TRD), a mental health condition that affects approximately 30% of people who suffer from major depressive disorder.  

Yaron Conforti, CEO and Director of Novamind said: “Under Dr. Robison’s leadership, Cedar Clinical Research has proven itself as a best-in-class research site for emerging mental health therapeutics. We’re excited to work with Merck, a world-class pharmaceutical company, to advance research for innovative mental health treatments.” 

Sit back, relax and watch this powerful interview with Yaron Conforti, CEO and Director of Novamind. 

Tags: , , , , ,

This entry was posted on Monday, March 22nd, 2021 at 5:22 pm and is filed under All Recent Posts, Novamind Inc.. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.